Experts Hope Coronavirus R&D Response Can Spur More Malaria Vaccine Research; Oxford To Start Final Stage Of Human Malaria Vaccine Trials
Devex: Just over $600M a year goes to malaria R&D. Can COVID-19 change that?
“The accelerated phase of vaccine development for the novel coronavirus has experts hopeful that it could have knock-on effects for other diseases, such as malaria. On average, malaria research and development have seen just over $600 million in investment annually from 2007 to 2018. … Total malaria R&D investment from 2007 to 2018 was over $7 billion, according to data from Policy Cures Research in the [World Malaria Report]. Of that total, about $1.8 billion went to vaccine R&D. In comparison, U.S. investments in vaccine R&D for COVID-19 this year through the Biomedical Advanced Research and Development Authority have exceeded $11 billion…” (Ravelo, 12/4).
The Guardian: Team behind Oxford Covid jab start final stage of malaria vaccine trials
“The Oxford team that has produced a successful coronavirus vaccine is about to enter the final stage of human trials in its quest for an inoculation against malaria. The Jenner Institute director, Prof. Adrian Hill, said the malaria vaccine would be tested on 4,800 children in Africa next year after early trials yielded promising results. … More than 400,000 people a year die of the disease, and in Africa a child under five dies every two minutes. … The vaccine could be in use by 2024 if the final human trials are successful, [Hill] said. It is regarded as a potentially huge breakthrough, given that no vaccine is fully licensed for malaria despite a century of research…” (Marsh, 12/5).